An increased serum level of free apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine

Nephron

Volumn 85, Issue 1, 2000, Pages 41-49

  Herrmann, Wolfgang ^a   Quast, Sabine ^a   Ellgass, Astrid ^a   Wolter, Kai ^b   Kiessig, Stefan T ^b   Molinari, Ewald ^c   Riegel, Werner ^d  

^a Zentrallabor der U   (Germany)

^b Hyland Immuno Division   (Germany)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Apolipoprotein(a); Haemodialysis; Lipoprotein(a); Nephrotic syndrome; Renal disease

Indexed keywords

APOLIPOPROTEIN A; HOMOCYSTEINE; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 0034054434     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045628     Document Type: Article

References (42)

1. Berg K: A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59:369-382.
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74: 758-765.
3. Herrmann W, Hanf S, Schmidt H, Kostner GM: Lp(a) - ein besonderes Lipoprotein mit atherogener Wirkung. Z Klin Med 1987;42: 1333-1336.
4. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-1251.
5. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G: Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia [see comments]. Lancet 1990;335:1360-1363.
6. Kark JD, Sandholzer C, Friedlander Y, Utermann G: Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: A case-control study in the Jerusalem population. Atherosclerosis 1993;98: 139-151.
7. Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997;17: 239-245.
8. Utermann G, Weber W: Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983;154:357-361.
9. Utermann G: The mysteries of lipoprotein(a). Science 1989;246:904-910.
10. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, Lawn RM, Scanu AM: Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84:3224-3228.
11. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-137.
12. Sommer A, Gorges R, Kostner GM, Paltauf F, Hermetter A: Sulphhydryl-selective fluorescence labeling of lipoprotein(a) reveals evidence for one single disulfide linkage between apoproteins(a) and B-100. Biochemistry 1991; 30:11245-11249.
13. While AL, Rainwater DL, Lanford RE: Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 1993;34:509-517.
14. Wilkinson J, Munro LH, Higgins JA: Apolipoprotein[a] is not associated with apolipoprotein B in human liver. J Lipid Res 1994;35:1896-1901.
15. Frank S, Durovic S, Kostner GM: Structural requirements of apo-a for the lipoprotein-a assembly. Biochem J 1994;304:27-30.
16. Ernst A, Helmhold M, Brunner C, Petho SA, Armstrong VW, Muller HJ: Identification of two functionally distinct lysine-bindingsites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270: 6227-6234.
17. Linton MF, Farese RV Jr, Chiesa G, Grass DS. Chin P, Hammer RE, Hobbs HH, Young SG: Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 1993;92:3029-3037.
18. White AL, Lanford RE: Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994;269:28716-28723.
19. Trieu VN, McConathy WJ: A two-step model for lipoprotein(a) formation. J Biol Chem 1995;270:15471-15474.
20. Callow MJ, Rubin EM: Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995; 270:23914-23917.
21. McCormick SP, Ng JK, Taylor S, Flynn LM, Hammer RE, Young SG: Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 1995;92:10147-10151.
22. Guevara J Jr, Valentinova NV, Garcia O, Gotto AM, Yang CY, Legal S, Gaubatz J, Sparrow JT: Interaction of apolipoprotein[a] with apolipoproteinB-100 Cys3734 region in lipoprotein[a] is confirmed immunochemically. J Protein Chem 1996;15:17-25.
23. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease [see comments]. Am J Kidney Dis 1996;27:1-25.
24. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 1996:125:91-101.
25. Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F: Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997;52: 1685-1692.
26. Greiber S, Wanner C: Lipoprotein(a) in nephrotic syndrome and end-stage renal disease. Miner Electrolyte Metab 1997;23:161-165.
27. Kim SB, Yang WS, Kang ES, Min WK, Park JS: Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Perit Dial Int 1997;17:236-242.
28. Stenvinkel P, Berglund L: Lipoprotein(a) in chronic renal disease. Miner Electrolyte Metab 1996;22:16-21.
29. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-120.
30. Elisaf MS, Bairaktari HT, Tzallas CS, Germanos N, Koulouridis E, Pappas MB, Siamopoulos KC, Tsolas O: Lipid parameters including Lp(a) in hemodialysis patients. Ren Fail 1994; 16:501-509.
31. Mooser V, Marcovina SM, White AL, Hobbs HH: Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996;98: 2414-2424.
32. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH: Apolipoprotein(a) kringle 4-containing fragments in human urine: Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996;97:858-864.
33. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM: Urinary excretion of apo(a) fragments: Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-911.
34. Kostner KM, Huber K, Stefenelli T, Rinner H, Maurer G: Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis 1997;129:103-110.
35. Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, Tamai T, Nakai T, Miyabo S: Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992;38:2244-2248.
36. Mooser V, Marcovina SM, Wang J, Hobbs HH: High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: Implications for plasma Lp(a) assay. Clin Genet 1997;52:387-392.
37. Kronenberg F, Kathrein H, Konig P, Never U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplingcr H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994;14:1405-1411.
38. Lochrer FMT, Angst CP, Brunner FP, Haefeli WE, Fowler B: Evidence for disturbed S-adenosylmethionine:S-adenosylhomocysteine ratio in patients with end-stage renal failure: A cause for disturbed methylation reactions? Nephrol Dial Transplant 1998;13:656-661.
39. Yeun JY: The role of homocysteine in end stage renal disease. Semin Dial 1998;11:95-101.
40. Harpel PC, Chang VT, Borth W: Homocysteine and other sulphhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulphhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89: 10193-10197.
41. Leerink CB, van Ham AD, Heeres A, Duif PF, Bouma BN, van Rijn HJ: Sulfhydryl compounds influence immunoreactivity, structure and functional aspects of lipoprotein(a). Thromb Res 1994;74:219-232.
42. Herrmann W, Quast S, Wolter K, Eger H, Kiessig ST, Hahmann H, Kreuter J, Molinari E: Determination of free apolipoprotein(a) in serum by immunoassay and its significance for risk assessment in patients with coronary artery disease. Clin Chem Lab Med 1999;37:21-28.